| Name | Title | Contact Details |
|---|
Apria Healthcare is one of the nation`s leading providers of home respiratory services and certain medical equipment, including oxygen therapy, inhalation therapies, sleep apnea treatment, and negative pressure wound therapy. Apria was the first such company to obtain voluntary accreditation from the Joint Commission and has been continuously accredited for more than 25 consecutive years. Apria operates more than 290 service locations throughout the United States and serves more than 2 million patients each year. In many cases, it`s a new beginning for its patients with the chance to return home from the hospital to resume their lives. What makes Apria industry leading is its focus on the patient as well as its employees. The people who work at Apria have passion and a commitment to excellence and we foster that compassion. Apria employees continually enhance their skills, receive training, and exhibit the kind of professionalism that makes Apria a highly effective and knowledgeable resource for our patients and healthcare customers.
NEA Medical Center is a Jonesboro, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
California Advanced Imaging is a Novato, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Morehead Memorial Hospital operates as a community hospital that provides various medical services to patients in Eden, North Carolina. It offers birthing center, cancer center, cardiac rehabilitation and chronic disease management, cardiopulmonary, day hospital, diagnostic imaging, emergency, intensive coronary care unit, laboratory, nursing center, occupational health, rehabilitation, sleep center, diagnostic center, wound healing center, and women’s diagnostic services. The company was founded in 1960 and is headquartered in Eden, North Carolina.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.